Procter & Gamble Company (The)NYSE: PG
Consumer Staples · Personal Care Products
$149.99
+4.60%
Vol: 983K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours. The most recent item, a Bernstein Market Perform initiation, is not dated within the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Procter & Gamble shares traded between $140.66-$143.22 on May 20 with RBC reiterating Buy (May 14); Q3 FY26 beat with first volume growth in a year.Neutral▶
Procter & Gamble shares traded between $140.66 and $143.22 on May 20. RBC Capital reiterated their Buy rating on May 14. The company reported Q3 FY26 results showing 3% organic sales growth (2% volume, 1% pricing) - the first volume growth in a year - with core EPS of $1.59 beating expectations. Adjusted gross margin contracted 100bps to 50% as reinvestments and cost pressures offset productivity gains. P&G recently raised its dividend for the 70th consecutive year (3% increase). Algorhythm announced an expanded contract with P&G India on May 14. Analyst consensus is Buy with average PT $163.77 (~15% upside).
May 20P&G shares jump ~4% after Q3 FY2026 beat with Core EPS $1.59 and revenue $21.23B up 7.4%, though tariffs remain a $400M after-tax headwind.Mixed▶
Procter & Gamble reported Q3 FY2026 Core EPS of $1.59 vs $1.55 consensus on revenue of $21.23B (+7.4% YoY), its fifth consecutive earnings beat. Shares gained roughly 4% on the print and the company hiked its dividend 3% to $1.0885 quarterly, marking the 70th consecutive annual increase. Tariffs represent a ~$400M after-tax headwind and Q3 core gross margin compressed 100 bps, signaling cost pressure that the company is offsetting through pricing and productivity. A weak Chinese consumer remains an Achilles' heel for the beauty segment (~20% of sales). CEO succession is also in focus, with COO Shailesh Jejurikar set to take over as CEO effective Jan 1, 2026 while Jon Moeller transitions to Executive Chairman. The setup mixes durable defensive cash flow with margin headwinds that could cap near-term upside.
May 19P&G shareholder narratives diverge as China beauty weakness and tariff pressures weigh on stock near $143Mixed▶
Procter & Gamble shares closed at $143.36 on May 15 with investor narratives sharply splitting on valuation as the consumer giant grapples with flat organic revenue and a 1% volume decline. Weak consumer spending in China remains a key headwind for its beauty segment, roughly one-fifth of total sales, and adjusted gross margin contracted 100 basis points to 50% on cost and mix pressures. Analysts maintain a Buy consensus with a near-term price target around $163.50 despite tariff exposure and margin compression. The stock is down about 4% recently as investors weigh resilience against persistent volume and FX challenges. Risk: continued China weakness and tariff cost pass-through could further pressure margins.
May 18RBC Capital reaffirms Buy on Procter & Gamble after Q3 FY26 print, but volume concerns and China beauty weakness keep stock range-bound near $143.Mixed▶
P&G traded around $143 in mid-May after its most recent earnings showed modest revenue growth and adjusted EPS that narrowly beat consensus, but adjusted EBITDA missed and volume softness weighed on the print. RBC Capital maintained its Buy rating on May 14, 2026, and the consensus 12-month price target sits near $163.62, implying ~15% upside. The company recently announced its 70th consecutive annual dividend raise, supporting a ~3% yield. Weak consumer spending in China remains a drag on the beauty segment, which is roughly one-fifth of sales. No fresh material news in the last 24 hours; flow has been driven by dividend coverage and analyst commentary. Risk: continued volume declines and FX headwinds could compress margins.
May 15P&G Q4 CY2025 results meet revenue, beat EPS but stock drops 1.9% on volume miss and EBITDA shortfallNegative▶
Procter & Gamble released Q4 CY2025 results on May 13, with revenue of $22.21B up 1.5% YoY matching the $22.29B estimate, and adjusted EPS of $1.88 beating $1.86 estimates. However, organic revenue was flat, sales volumes dipped 1%, and adjusted EBITDA of $6.39B missed $6.46B consensus, sending shares down 1.9% to $143.31. Management reiterated full-year adjusted EPS guidance at $6.96 midpoint. PG closed May 14 at $142.83, near its 52-week low of $137.62. Risk: persistent volume softness and margin pressure from higher costs question pricing power going forward.
May 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 13Procter & Gamble shares pull back to $148 from $171 high; Zacks Research cuts FY2026 EPS estimates May 7 amid cost pressures.Negative▶
Procter & Gamble shares have pulled back from a 52-week high near $171 to ~$148 in early May 2026, with the 52-week low at $137.62. April earnings showed Q3 FY26 sales of about $21.2B (slightly below forecasts of $21.24B) and EPS of $1.59 (slightly ahead of consensus). Organic sales grew 3%, with 2 percentage points from volume and 1 from price. Zacks Research cut its FY2026 EPS estimates on May 7. The stock decline is partially attributed to higher oil prices and related input-cost pressures, alongside competitive pressures in the personal care market. No major new positive catalysts emerged in the last 48 hours.
May 12Zacks Research cut FY2026 EPS estimates for Procter & Gamble on May 7 as shares lag the S&P 500 by ~38 points over the past year despite Q3 beat.Mixed▶
Zacks Research lowered its FY2026 EPS estimates for P&G in a research note dated May 7. The cut comes despite a Q3 fiscal 2026 beat where all ten product categories grew organically with strong North America and China volume. P&G's share price is down 8.2% over the past year through May 7 while the S&P 500 has gained 30.3%. The board raised the quarterly dividend 3% to $1.0885, extending its 70-year streak of annual hikes. UBS lifted its PT to $172 from $166 and BofA to $170 from $167. PG closed near $146.42 on May 8 with a Buy consensus from 13 analysts. Risk: moderating growth and rich valuation.
May 11Procter & Gamble flags higher commodity and tariff costs after Q3 beat as analysts publish FY26 forecast updatesMixed▶
Procter & Gamble's Q3 FY2026 results beat both revenue and non-GAAP profit expectations, with broad-based volume growth driven by Skin/Personal Care launches and product innovation; all ten product categories grew organically, and North America and China contributed meaningfully. The beauty segment led with 7% organic growth vs 2.4% expected, and Baby/Feminine/Family Care delivered 3% vs 1.4% expected. However, management warned higher commodity costs and tariffs would be a negative force for the remainder of fiscal year, and weak Chinese consumer spending remains an Achilles' heel for the beauty segment (~20% of sales). Marketbeat published a fresh round of FY26 analyst earnings predictions on May 8. PG was named #1 in Household Products on Fortune's 2026 America's Most Innovative Companies list. Stock at ~$146.44 with Buy consensus and ~$163.64 average PT.
May 8Procter & Gamble Q3 FY2026 organic sales grew 2% with 3% core EPS growth; stock up 2.2% May 6 as market anticipates continued momentum.Positive▶
Procter & Gamble delivered strong third quarter fiscal 2026 results with net sales of $84.3 billion (up 2%), 2% organic sales growth and 4% core EPS growth, along with $17.8 billion in operating cash flow. The stock gained approximately 4% post-earnings as the company exceeded analyst expectations despite supply chain challenges linked to the Iran war impacting costs. P&G reported 52-week range of $137.62 to $170.99. The company continues to innovate with new product launches targeting brand growth through targeted campaigns. Analyst consensus maintains a Buy rating with average 12-month price target of $163.64, representing 11.11% upside. P&G faces margin pressures from higher costs and increased investments in marketing.
May 6Procter & Gamble Q3 earnings beat with first volume growth in a year; stock rises 3%Positive▶
Procter & Gamble reported Q3 2026 net sales of $21.24 billion (vs. estimates), +7% with organic growth of 3%, and achieved first volume growth in a year. The company reiterated full-year earnings and sales forecast. Management warned of $150 million Q4 headwind from elevated fuel costs and $1 billion potential annual after-tax hit if Brent crude stays near $100/barrel. UBS raised price target to $172 from $166 on April 27.
May 5P&G beats Q1 estimates with 7.4% YoY growth; UBS raises PT to $172Positive▶
Procter & Gamble reported Q1 revenue of $21.24B vs. $20.5B expected, with +4% core EPS growth to $1.59. The company cited volume growth and product innovation in Skin & Personal Care as key drivers. UBS raised its price target to $172 from $166 on April 27, maintaining a Buy rating. The stock trades at $143.10, down modestly from the earnings beat. Key risk: inflation pressures and weak consumer demand require continued cost discipline.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| PGPROCTER | $149.99 | +4.60% | +0.7% | 20.2x | 0.40 | $333.9B |
| KVUEKENVUE | $18.29 | +4.73% | +1.6% | 14.2x | 0.52 | $33.5B |
| ELESTEE | $90.90 | +15.19% | -1.4% | 24.8x | 1.21 | $28.5B |
| WMTWALMART | $119.55 | -1.48% | -9.0% | 36.8x | 0.65 | $967.2B |
| COSTCOSTCO | $973.70 | -7.31% | -2.4% | 46.6x | 0.91 | $466.0B |
| KOCOCA | $80.93 | -0.30% | -0.0% | 23.3x | 0.36 | $349.2B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.